Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

XLO

Xilio Therapeutics (XLO)

Xilio Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:XLO
DateTimeSourceHeadlineSymbolCompany
02/04/202407:05GlobeNewswire Inc.Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:XLOXilio Therapeutics Inc
28/03/202422:05GlobeNewswire Inc.Xilio Therapeutics Announces $11.3 Million Private Placement Equity FinancingNASDAQ:XLOXilio Therapeutics Inc
28/03/202422:00Business WireGilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 ProgramNASDAQ:XLOXilio Therapeutics Inc
28/03/202422:00GlobeNewswire Inc.Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 ProgramNASDAQ:XLOXilio Therapeutics Inc
29/02/202408:01GlobeNewswire Inc.Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care ConferenceNASDAQ:XLOXilio Therapeutics Inc
01/02/202408:01GlobeNewswire Inc.Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology ConferenceNASDAQ:XLOXilio Therapeutics Inc
20/01/202408:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XLOXilio Therapeutics Inc
08/01/202423:30GlobeNewswire Inc.Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology TherapiesNASDAQ:XLOXilio Therapeutics Inc
04/01/202408:38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XLOXilio Therapeutics Inc
04/01/202408:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XLOXilio Therapeutics Inc
04/01/202408:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XLOXilio Therapeutics Inc
04/01/202408:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XLOXilio Therapeutics Inc
07/12/202323:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XLOXilio Therapeutics Inc
07/12/202323:30GlobeNewswire Inc.Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy DataNASDAQ:XLOXilio Therapeutics Inc
10/11/202308:17Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:XLOXilio Therapeutics Inc
10/11/202308:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XLOXilio Therapeutics Inc
10/11/202308:10Edgar (US Regulatory)Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]NASDAQ:XLOXilio Therapeutics Inc
10/11/202308:08Edgar (US Regulatory)Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]NASDAQ:XLOXilio Therapeutics Inc
10/11/202308:05Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:XLOXilio Therapeutics Inc
10/11/202308:01GlobeNewswire Inc.Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial ResultsNASDAQ:XLOXilio Therapeutics Inc
04/11/202307:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XLOXilio Therapeutics Inc
04/11/202303:00GlobeNewswire Inc.Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid TumorsNASDAQ:XLOXilio Therapeutics Inc
01/11/202300:15GlobeNewswire Inc.Xilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual MeetingNASDAQ:XLOXilio Therapeutics Inc
28/09/202307:02GlobeNewswire Inc.Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual MeetingNASDAQ:XLOXilio Therapeutics Inc
08/09/202306:26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XLOXilio Therapeutics Inc
08/09/202306:23Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:XLOXilio Therapeutics Inc
05/09/202322:35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XLOXilio Therapeutics Inc
05/09/202322:30GlobeNewswire Inc.Xilio Therapeutics Announces Promotion of Katarina Luptakova, M.D., to Chief Medical Officer and Scott Coleman, Ph.D., to Chief Development OfficerNASDAQ:XLOXilio Therapeutics Inc
05/09/202321:30GlobeNewswire Inc.Xilio Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare ConferenceNASDAQ:XLOXilio Therapeutics Inc
19/08/202310:40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XLOXilio Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:XLO